This is supported by additional studies of cancer cell lines that showed that partial depletion of ARID1A enhanced cell proliferation [47,48] and restoring expression of ARID1A in both ARID1A-deficient breast cancer cell lines and mouse ovarian cancer models was sufficient to inhibit cell proliferation [48,49]. Here, ARID1A is linked to ovarian carcinoma.